The FDA has approved Roche (OTCQX:RHHBY) unit Genentech’s Tecentriq (atezolizumab), combined with chemo agents carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer
More than 1,200 children were diagnosed with some form of cancer over a 10 year period in Scotland, statistics have revealed. From 2007 to 2016, 1,275 people aged 14 or
Avacta plc (LON: AVCT) Affimer Innovative Immunotherapies Presentation Feb 2019 by CEO Alastair Smith. Avacta’s principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to
Avacta Group plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the latest update to the market. Alastair talks us through the highlights, provides us with some details around
Avacta Group Plc (LON:AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant technical
Dr Alastair Smith, Avacta Group Chief Executive Officer, commented: “I am delighted to report that Moderna has exercised its option to enter into this exclusive license agreement with respect to
Affimer technology offers unique solutions in the field of affinity purification through the ability to develop highly specific and stable capture reagents for a wide-range of novel targets. The robust
At Avacta Group Plc (LON: AVCT) our mission is to shape the future of medicine by developing safe and efficacious drugs based on our proprietary Affimer® platform and by providing
Dr Eliot Forster, Chairman of Avacta Group, commented: “I am delighted that Dr Williams is joining Avacta and very much look forward to working with him. Sam has extensive experience
Alastair Smith, Chief Executive of Avacta Group commented: “I am delighted that Dr Jose Saro is joining Avacta to lead the therapeutic development strategy and to drive the in-house Affimer®
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
